ES2185472B1 - Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas. - Google Patents

Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.

Info

Publication number
ES2185472B1
ES2185472B1 ES200100151A ES200100151A ES2185472B1 ES 2185472 B1 ES2185472 B1 ES 2185472B1 ES 200100151 A ES200100151 A ES 200100151A ES 200100151 A ES200100151 A ES 200100151A ES 2185472 B1 ES2185472 B1 ES 2185472B1
Authority
ES
Spain
Prior art keywords
transcription
treatment
expression products
cancer cells
slug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100151A
Other languages
English (en)
Other versions
ES2185472A1 (es
Inventor
Isidro Sanchez Garcia
Alberto Orfao De Matos
Jesus Perez Losada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Salamanca
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Salamanca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200100151A priority Critical patent/ES2185472B1/es
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Salamanca filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to PCT/ES2002/000026 priority patent/WO2002059361A1/es
Priority to EP20020710865 priority patent/EP1354962B1/en
Priority to US10/466,817 priority patent/US7776519B2/en
Priority to ES02710865T priority patent/ES2339335T3/es
Priority to AT02710865T priority patent/ATE454467T1/de
Priority to JP2002559843A priority patent/JP2004520045A/ja
Priority to DE60234991T priority patent/DE60234991D1/de
Priority to ES200202633A priority patent/ES2241402B1/es
Priority to ES200202634A priority patent/ES2242469B1/es
Publication of ES2185472A1 publication Critical patent/ES2185472A1/es
Application granted granted Critical
Publication of ES2185472B1 publication Critical patent/ES2185472B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Empleo del gen Slug, o de sus productos de transcripción o expresión, en la detección y/o tratamiento de células cancerosas.
La expresión aberrante del gen Slug o de sus productos de transcripción o expresión permite detectar la presencia de células cancerosas, en particular, células tumorales mesenquimales, en una muestra biológica sospechosa de contener dichas células malignas. El gen Slug, o sus productos de transcripción o expresión pueden ser utilizados en el tratamiento del cáncer.
ES200100151A 2001-01-23 2001-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas. Expired - Fee Related ES2185472B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES200100151A ES2185472B1 (es) 2001-01-23 2001-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.
DE60234991T DE60234991D1 (de) 2001-01-23 2002-01-23 Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen
US10/466,817 US7776519B2 (en) 2001-01-23 2002-01-23 Use of the slug gene, or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
ES02710865T ES2339335T3 (es) 2001-01-23 2002-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o el tratamiento de celulas cancerosas.
AT02710865T ATE454467T1 (de) 2001-01-23 2002-01-23 Verwendung des slug-gens oder der transkriptions- oder expressionsprodukte davon beim nachweis und/oder bei der behandlung von krebsartigen zellen
JP2002559843A JP2004520045A (ja) 2001-01-23 2002-01-23 癌細胞を検出および／または治療するためにＳｌｕｇ遺伝子またはその遺伝子の転写もしくは発現生成物を使用する方法。
PCT/ES2002/000026 WO2002059361A1 (es) 2001-01-23 2002-01-23 Empleo del gen slug o de sus productos de transcripcion o expresion en la deteccion y/o tratamiento de celulas cancerosas
EP20020710865 EP1354962B1 (en) 2001-01-23 2002-01-23 Use of the slug gene or of the transcription or expression products thereof in the detection and/or treatment of cancerous cells
ES200202633A ES2241402B1 (es) 2001-01-23 2002-11-15 Metodo para el screening in vitro de agentes antitumorales basados en la regulacion de la expresion del gen slug.
ES200202634A ES2242469B1 (es) 2001-01-23 2002-11-15 Composicion farmaceutica para el tratamiento del cancer.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100151A ES2185472B1 (es) 2001-01-23 2001-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.

Publications (2)

Publication Number Publication Date
ES2185472A1 ES2185472A1 (es) 2003-04-16
ES2185472B1 true ES2185472B1 (es) 2004-10-16

Family

ID=8496481

Family Applications (4)

Application Number Title Priority Date Filing Date
ES200100151A Expired - Fee Related ES2185472B1 (es) 2001-01-23 2001-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.
ES02710865T Expired - Lifetime ES2339335T3 (es) 2001-01-23 2002-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o el tratamiento de celulas cancerosas.
ES200202633A Expired - Fee Related ES2241402B1 (es) 2001-01-23 2002-11-15 Metodo para el screening in vitro de agentes antitumorales basados en la regulacion de la expresion del gen slug.
ES200202634A Expired - Fee Related ES2242469B1 (es) 2001-01-23 2002-11-15 Composicion farmaceutica para el tratamiento del cancer.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES02710865T Expired - Lifetime ES2339335T3 (es) 2001-01-23 2002-01-23 Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o el tratamiento de celulas cancerosas.
ES200202633A Expired - Fee Related ES2241402B1 (es) 2001-01-23 2002-11-15 Metodo para el screening in vitro de agentes antitumorales basados en la regulacion de la expresion del gen slug.
ES200202634A Expired - Fee Related ES2242469B1 (es) 2001-01-23 2002-11-15 Composicion farmaceutica para el tratamiento del cancer.

Country Status (7)

Country Link
US (1) US7776519B2 (es)
EP (1) EP1354962B1 (es)
JP (1) JP2004520045A (es)
AT (1) ATE454467T1 (es)
DE (1) DE60234991D1 (es)
ES (4) ES2185472B1 (es)
WO (1) WO2002059361A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2195751B1 (es) * 2001-11-27 2005-04-01 Universidad De Salamanca (Otri) Mamiferos no humanos transgenicos como modelos para patologias humanas con origen en celulas stem.
ES2253028B1 (es) * 2003-05-30 2007-08-01 Universidad De Salamanca "empleo del gen slug, sus productos de transcripcion o expresion, y/o compuestos inhibidores o estimuladores de la expresion de slug para conferir radioresistencia o radioproteccion celular.
ES2301268B1 (es) * 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
CA2656548A1 (en) * 2005-06-30 2007-01-11 Whitehead Institute Progenitor cells and uses thereof
WO2010003103A2 (en) * 2008-07-02 2010-01-07 Whitehead Institute For Biomedical Research Non-human mammals with t or b cells having predefined specificity
KR101805181B1 (ko) 2016-09-02 2017-12-07 충북대학교 산학협력단 인산화된 slug 단백질의 유사분열 세포에 대한 신규한 바이오 마커로서의 용도
WO2023126958A1 (en) * 2021-12-30 2023-07-06 Mestastop Solutions Private Limited Method for producing a spontaneous metastasis model
CN116747309B (zh) * 2023-06-20 2025-12-05 中山大学 Slug抑制剂在制备华支睾吸虫细胞外囊泡诱导的胆管癌的治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP2007516693A (ja) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COHEN, M.E. et al. "Human SLUG gene organization, expression, and chromosome map location on 8q", GENOMICS, 1998, Vol. 51, páginas 468-471. Todo el documento. *
HEMAVATHY, K. et al. "Human Slug is a repressor that localizes to sites of active transcription", MOLECULAR AND CELLULAR BIOLOGY, 2000, Vol. 26, Nº 14, páginas 5087-5095. Todo el documento. *
HEMAVATHY, K. et al. "Snail/Slug family of repressors: Slowly going into the fast lane of development and cancer", GENE, 2000, Vol. 257, páginas 1-12. Todo el documento. *
INUKAI, T. et al. "Identification of the antiapoptotic zinc-finger transcription factor SLUG as a downstream target of E2A-HLF oncogenic fusion protein". En: "40th Annual Meeting of the American Society of Hematology; Miami Beach, Florida, USA; Diciembre 4-8, 1998". Publicado en: BLOOD, 1998, Nº 10, suppl. 1 part 1-2, página 479 A. Todo el documento. *
INUKAI, T. et al. "Slug, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein", MOLECULAR CELL, 1999, Vol. 4, páginas 343-352. Todo el documento. *
SAVAGNER, P. et al. "The zinc-finger protein Slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition", THE JOURNAL OF CELL BIOLOGY, 1997, Vol. 137, Nº 6, páginas 1403-1419. Todo el documento. *
SEIDEL, M.G. et al. "Slug, a leukemogenic zinc finger transcriptional repressor inhibits apoptosis in hematopoietic progenitors". En: "Annual Meeting of the German and Austrian Society for Hematology and Oncology; Graz, Austria; Octubre 21-25, 2000". Publicando en: ONKOLOGIE, 2000, Vol. 23, página 5. Todo el documento. *

Also Published As

Publication number Publication date
EP1354962A1 (en) 2003-10-22
ES2241402B1 (es) 2007-02-16
ATE454467T1 (de) 2010-01-15
JP2004520045A (ja) 2004-07-08
US20060141454A1 (en) 2006-06-29
US7776519B2 (en) 2010-08-17
DE60234991D1 (de) 2010-02-25
ES2242469B1 (es) 2006-07-16
ES2242469A1 (es) 2005-11-01
ES2241402A1 (es) 2005-10-16
EP1354962B1 (en) 2010-01-06
ES2185472A1 (es) 2003-04-16
ES2339335T3 (es) 2010-05-19
WO2002059361A1 (es) 2002-08-01

Similar Documents

Publication Publication Date Title
Ghorbani et al. Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review
Butz et al. Exosomal microRNAs are diagnostic biomarkers and can mediate cell–cell communication in renal cell carcinoma
McDowell et al. Leading the invasion: The role of Cathepsin S in the tumour microenvironment
Chik et al. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2′-deoxycytidine
ATE343003T1 (de) Amplifizierung von nukleinsäuresequenzen mittels multiplex priming
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
ES2191018T3 (es) Procedimiento para detectar micrometastasis de cancer de prostata.
ES2185472B1 (es) Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.
DE602004015626D1 (de) Bei brustkrebs
CO6260156A2 (es) Cebadores y sendas para la detecciondel estado de metilacion de un gen, incluyendo el gen mage-a3
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
NO20024240L (no) Nye arylfruktose-1,6-bisfosfataseinhibitorer
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2002010436A3 (en) Prognostic classification of breast cancer
WO2008103971A3 (en) Prostate cancer survival and recurrence
ES2575697T3 (es) Métodos y sondas para detectar cáncer de esófago
Party Evidence for novel non-angiogenic pathway in breast-cancer metastasis
ATE259425T1 (de) Mitochondriale, als tumormarker geeignete mutationen, die nur ein basenpaar betreffen
AR048945A1 (es) Pronostico para leucemia mieloide cronica
ATE333521T1 (de) Detektion von vancomycin-resistenten enterococcus-subspezies
CY1105566T1 (el) Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση
Kawasaki et al. Detection of aberrant methylation of tumor suppressor genes in plasma from cancer patients
NZ584656A (en) Mitochondrial dna deletion between about residues 12317-16254 for use in the detection of cancer
DK1625142T3 (da) Markører for præcancer- og cancerceller og fremgangsmåde til interferering med celleproliferation deri
Owusu-Apenten et al. Curcumin restores glutathione-S-transferase activity for LNCaP prostate cancer cells

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030416

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2185472B1

Country of ref document: ES

GD2A Contractual licences

Effective date: 20100427

FD2A Announcement of lapse in spain

Effective date: 20190521

FD2A Announcement of lapse in spain

Effective date: 20190604